肺炎支原体感染患儿肺外并发症的危险因素分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the risk factors of extrapulmonary complications in children with Mycoplasma pneumoniae infection.Methods The clinical data of 100 children with Mycoplasma pneumoniae infection who were treated in Pingxiang People′s Hospital,Jiangxi Province from February 2018 to November 2019 were retrospectively analyzed.All the children were assigned into groups according to the presence and absence of extrapulmonary complications,the clinical data of 55 children without extrapulmonary complications were included in control group,and the clinical data of 45 children with extrapulmonary complications were included in observation group.The risk factors for extrapulmonary complications in children with Mycoplasma pneumoniae infection were recorded and analyzed.Results The gender and duration of fever between the two groups were compared,and the difference was not statistically significant (P＞0.05).The proportion of age ＜6 years old,course of disease ＞14 d,start time of antibiotic use＞4 d,C-reactive protein (CRP) ＞10 mg/L,procalcitonin (PCT) ＞0.25 ng/mL,and pulmonary consolidation shadow in the observation group was higher than that in the control group,with statistical differences (P＜0.05).The results of Logistic multivariate analysis showed that age ＜6 years old,course of disease ＞14 d,start time of antibiotic use ＞4 d,CRP ＞10 mg/L,PCT ＞0.25 ng/mL,and pulmonary consolidation shadow were the risk factors for extrapulmonary complications in children with Mycoplasma pneumoniae infection (OR＞1,P＜0.05).Conclusion Younger age,longer course of disease,delayed start time of antibiotic use,elevated CRP,elevated ESR,and occurrence of pulmonary consolidation shadow are the risk factors for extrapulmonary complications in children with Mycoplasma pneumoniae infection.

Key words： Mycoplasma pneumoniae infection Children Extrapulmonary complications Risk factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WAN Fang
	CHEN Si

Cite this article:

WAN Fang,CHEN Si. Analysis of the risk factors of extrapulmonary complications in children with Mycoplasma pneumoniae infection[J]. 中国当代医药, 2020, 27(34): 126-128.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I34/126

[1]	骆明，卢杰，颜科.小儿肺炎支原体感染致肺外并发症120例临床分析[J].中国医药科学，2014，4（4）：195-197.
[2]	蒋星华，周良芳，邓剑，等.儿童肺炎支原体感染920例临床分析[J].中南医学科学杂志，2019，47（2）：195-197.
[3]	赵悦彤.肺炎支原体肺炎常见远期并发症的研究进展[J].国际儿科学杂志，2019，46（1）：36-39.
[4]	胡亚美，江戴芳，申昆玲，等.诸福棠实用儿科学[M].北京：人民卫生出版社，2005：1252-1262.
[5]	崔捷.儿童支原体肺炎92例肺外损害临床分析[J].中国药物与临床，2019，19（22）：3911-3912.
[6]	林新春.小儿肺炎支原体感染后发生喘息的危险因素分析[J].中国民康医学，2019，31（20）：87-89.
[7]	雷加萍，李远西，何亚薇.小儿肺炎支原体感染现状及其肺外损害相关实验室检测临床分析[J].四川医学，2013，34（2）：287-289.
[8]	鲁承熙.儿童肺炎支原体感染肺外并发症临床分析[J].吉林医学，2015，36（14）：2974-2975.
[9]	范丽，邓芸.住院儿童不同年龄支气管哮喘临床特点[J].贵州医药，2019，43（3）：401-402.
[10]	叶玲飞，王宁玲.儿童肺炎支原体感染肺外损害166例分析[J].安徽医药，2019，23（5）：929-932.
[11]	徐桂红，李波，李洪臣.神经内科下呼吸道感染者抗生素合理应用研究[J].山西医药杂志，2020，49（2）：208-211.
[12]	陈远革.糖皮质激素辅助治疗儿童肺炎支原体大叶性肺炎的临床效果[J].中国当代医药，2019，26（17）：95-97.
[13]	张晓芬.C反应蛋白与小儿支原体肺炎的相互关系研究[J].中国药物与临床，2018，18（4）：601-603.
[14]	孙菲.肺炎支原体感染患儿发生肺外并发症的影响因素研究[J].临床和实验医学杂志，2014，14（9）：748-751.
[15]	荣强全，王静，郝海燕，等.早期联合检测PCT 与CRP 水平早期鉴别支原体感染肺炎和细菌性感染肺炎患儿的价值探讨[J].湖南师范大学学报（医学版），2019，16（3）：159-162.